<DOC>
	<DOC>NCT01653470</DOC>
	<brief_summary>The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in subjects with advanced or metastatic solid tumors</brief_summary>
	<brief_title>Study to Evaluate Safety &amp; Tolerability of BMS-906024 in Combination With Chemotherapy &amp; to Define DLTs &amp; MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors</brief_title>
	<detailed_description>DLTs = dose-limiting toxicities MTD = Maximum tolerated dose</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Subjects with advanced or metastatic solid tumors for whom a chemotherapy regimen is considered appropriate Subjects with nonsmall cell lung cancer and triplenegative breast cancer are preferred Biopsy accessible tumor (may use archived tumor samples under certain circumstances) Life expectancy of at least 3 months Eastern Cooperative Oncology Group (ECOG) Performance Status of 01 Measurable disease Uncontrolled brain metastases Infection Gastrointestinal (GI) disease with increased risk of diarrhea (e.g. inflammatory bowel disease) Uncontrolled or significant cardiovascular disease Subjects taking medications known to increase risk of Torsades de Pointes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>